Shorla Oncology Shorla Oncology (also known as Shorla Pharma) is a pharmaceutical company that develops cancer treatment solutions. | ![]() OS Therapies OS Therapies (OST) is a therapeutic company focused on identifying, developing, and commercializing treatments for osteosarcoma. | ![]() Citius Oncology Citius Oncology is a company that operates a platform to develop and commercialize novel targeted oncology therapies. | ![]() Emtora Biosciences Emtora Biosciences is a life science company developing eRap, a formulation of rapamycin for the prevention of cancer progression/recurrence. | ||
Founding Date | Founding Date 2018 | Founding Date 2018 | Founding Date 2021 | Founding Date 2023 | Founding Date N/A |
Type | Type Private | Type Public | Type Public | Type Private | Type Private |
Tags | |||||
Locations | Locations Clonmel, IE HQ Cambridge, US | Locations Rockville, US HQ | Locations New York, US HQ | Locations Philadelphia, US HQ | Locations San Antonio, US HQ |
Employees | Employees 4914% increase | Employees 4 | Employees N/A | Employees 5 | Employees 2 |
Valuation ($) | Valuation ($) N/A | Valuation ($) 55.5 m | Valuation ($) 86.6 m | Valuation ($) N/A | Valuation ($) N/A |
Funding | |||||
Latest funding round | Latest funding round $ 35m (over 2 years ago) | Latest funding round N/A | Latest funding round N/A | Latest funding round N/A | Latest funding round $ 3m (over 6 years ago) |
Total funding raised | Total funding raised $ 43.3m | Total funding raised $ 6m | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 3m |

OS Therapies (OST) is a therapeutic company focused on identifying, developing, and commercializing treatments for osteosarcoma.
View company
Citius Oncology is a company that operates a platform to develop and commercialize novel targeted oncology therapies.
View company
SyzOnc is a company that develops immunotherapy solutions.
View company
Emtora Biosciences is a life science company developing eRap, a formulation of rapamycin for the prevention of cancer progression/recurrence.
View company